Matthew Sykes
Stock Analyst at Goldman Sachs
(4.02)
# 502
Out of 5,173 analysts
210
Total ratings
52.38%
Success rate
10.01%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $9.75 | -48.72% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $4.71 | -36.31% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $19.14 | -66.04% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $34.86 | +29.09% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $4.66 | +71.67% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $44.50 | +7.87% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $13.88 | +22.48% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $100.35 | +59.44% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $8.10 | +23.46% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $87.16 | +43.41% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $7.59 | +84.45% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $190.00 | +26.32% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $17.56 | +48.06% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $158.00 | +7.59% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $84.96 | -34.09% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $72.14 | +10.90% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.39 | +7.91% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $200.09 | -5.04% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $3.62 | -51.66% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $3.07 | +38.44% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $33.54 | +10.32% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $104.91 | -38.04% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $166.96 | +49.74% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $3.94 | +509.14% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,239.07 | +4.92% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $6.99 | +71.67% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $478.12 | +33.86% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $112.02 | +29.44% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $39.49 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $9.75
Upside: -48.72%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $4.71
Upside: -36.31%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $19.14
Upside: -66.04%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $34.86
Upside: +29.09%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $4.66
Upside: +71.67%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $44.50
Upside: +7.87%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $13.88
Upside: +22.48%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $100.35
Upside: +59.44%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $8.10
Upside: +23.46%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $87.16
Upside: +43.41%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $7.59
Upside: +84.45%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $190.00
Upside: +26.32%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $17.56
Upside: +48.06%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $158.00
Upside: +7.59%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $84.96
Upside: -34.09%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $72.14
Upside: +10.90%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.39
Upside: +7.91%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $200.09
Upside: -5.04%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $3.62
Upside: -51.66%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $3.07
Upside: +38.44%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $33.54
Upside: +10.32%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $104.91
Upside: -38.04%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $166.96
Upside: +49.74%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $3.94
Upside: +509.14%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,239.07
Upside: +4.92%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $6.99
Upside: +71.67%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $478.12
Upside: +33.86%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $112.02
Upside: +29.44%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $39.49
Upside: -